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RATS are  commonly  used  in  anaphylaxis  models,
mainly  in  intestinal  anaphylaxis.  Hypersensitivity
mechanisms  are  complex  and they  are  not clearly
defined.  Ovalbumin  (OVA)  is  commonly  used  for
studies on the hypersensitivity mechanism. However,
the potential pro-inflammatory mediators induced by
this antigen in the model of paw oedema in immu-
nized rats are still not completely understood. This
work examines the pharmacological modulation of
several mediators involved in rat hind paw immune
oedema induced by OVA. Wistar rats were previously
immunized  (14–18  days)  with  OVA  (30m g,  intra-
peritoneally)  or  sham-sensitized  with  aluminum
hydroxide (control).  The paw  volumes  were  meas-
ured before the antigenic stimuli and 1, 2, 3 and 4h
after the intraplantar injection of OVA (10m g/paw).
Subcutaneous injection of dexamethasone, diphenhy-
dramine, cyproheptadine, chlorpromazine or methy-
sergide significantly inhibited (p < 0.05) the allergic
paw oedema. The dual inhibitor of cyclooxygenase
and lipoxygenase (NDGA), the cyclooxygenase inhib-
itor (indomethacin), the lipoxygenase inhibitor (MK-
886),  the PAF  antagonist (WEB 2086),  the mast  cell
stabilizer (ketotifen), and the anti-histamine (mecli-
zine) did not inhibit the immune oedema. In addition,
thalidomide and pentoxifylline (anti-tumour necrosis
factor  drugs)  were  ineffective  against  OVA-induced
oedema. The fact that indomethacin, MK-886, NDGA
and  WEB  2086  are  unable  to  inhibit  this  allergic
oedema  indicates  that  the  dexamethasone  action
seems not to be via phospholipase A2, but possibly
due to the synthesis and/or the inhibitory activity of
cytokines. The paw oedema inhibition by diphenhy-
dramine, but not by meclizine, may suggest a differ-
ent mechanism, which is independent of the effect of
histamine. These data indicate that allergic oedema is
more sensitive to anti-serotonin drugs, mainly anti-
5-HT2, suggesting that the principal mediator of this
inflammatory response is serotonin.
Key words: Rat paw immune oedema, Anti-inflammatory
drug, Anti-allergic drug, Ovalbumin
Introduction
Allergic  processes are  complex  disorders  in  which
inflammatory  and  immunological  mechanisms  are
involved. One of the most important approaches used
in the examination of the immunopathological mech-
anisms of anaphylactic and inflammatory disorders is
to  elicit  the  formation  of  paw  oedema,  injecting
various substances into the subplantar tissue of rats or
mice.1 Inflammation often occurs after a subplantar
injection of a number of substances in the hind paw
of rats or mice. Many anti-inflammatory drugs have
been  tested  for  their  ability  to  inhibit  hind  paw
oedema.
The  vasoactive amines,  histamine  and  serotonin,
play a crucial role in type I hypersensitivity.2–4 The
most important vasoactive mediators that are stored
in mast cells and basophil granules are histamine in
humans, as well as serotonin (5-hydroxytryptamine)
in rodents. Histamine was one of the first inflamma-
tory  mediators  thought  to  be  important  in  the
pathophysiology  of  asthma.5 Like  histamine,  ser-
otonin is also capable of increasing vascular permea-
bility,  of  dilating  capillaries  and  of  producing  the
contraction  of  non-vascular  smooth  muscles.  Most
serotonin is stored in the gastrointestinal tract and the
central  nervous system, but  a  large  amount  is  also
stored in the dense granules of platelets.6
Rats are commonly used in  the study  of  anaphy-
laxis,  particularly  those  involving  the  intestinal
tract.7,8 Pre-clinical  studies  are  necessary  for  pro-
spective research on physiopathology of food allergy.
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Mediators of Inflammation, 11, 155–163 (2002)There  have been  no studies, to  our  knowledge,  of
paw oedema specifically induced by ovalbumin (OVA)
antigen  in  the  rat. To  perform  studies  in  intestinal
hypersensitivity, we decided to evaluate the potency
of  OVA  using  this  antigen  for  immunization  in  the
model  of  rat  hind  paw  oedema. This  study  investi-
gated the protective effect of several pharmacological
inhibitors in the course of the immune oedema, to
determine which mediators are involved in antigen-
induced oedema. We initially investigated the impor-
tance of  classic  antagonists  of  inflammation  in  the
development of antigen-induced oedema, in the paws
of  sensitized  rats.  The  protective  effects  of  anti-
histamine and anti-allergic agents against anaphylactic
oedema were also studied.
Materials and methods
Animals
Wistar rats (130–230g  body weight)  of both sexes
were housed in a room with free access to water and
food until used. All animals were supplied by Clinical
Research Unit, Federal University of Cear´ a, and the
protocol complied with the Occupational Health and
Safety in the Care and Use of Research Animals.
Sensitization procedure
OVA was dissolved in phosphate-buffered saline (PBS)
and mixed with an equal volume of coloidal alumin-
ium hydroxide, Al(OH)3. The rats were sensitized on
day 0 by intraperitoneal (i.p.) injections of 30mg of
OVA/rat dispersed in 0.5ml of PBS and Al(OH)3. The
control rats were injected with an emulsion contain-
ing equal volumes of PBS and Al(OH)3.
Quantification of immune paw oedema
Fourteen to 18 days after the injection of antigen to
sensitization or Al(OH)3 (sham-sensitization), the ani-
mals  received  an  intraplantar injection of  10mg  of
OVA in the right hind paw, diluted in 100ml of PBS.
The  volume  of  the  hind  paw  of  each  animal  was
measured  by  plethysmograph  (7150  plethysmo-
mether; Ugo Basile, Varese, Italy) before the injection
of  the inflammatory challenge (time 0) and 1, 2, 3
and  4h  after  the  challenge.  The  increase  in  paw
volume (D volume) was obtained by subtracting the
paw  volume  measured  prior  to  the  application  of
stimuli  from  the  volumes  for  the  different  time-
points. The results were expressed as the increase in
paw volume (ml) calculated by subtracting the basal
volume. The area under the time-course curve was
also calculated and the results expressed in arbitrary
units.9,10
Drug modulation of OVA-induced paw oedema
in immunized rats
In the present study employing specific antagonists,
we investigated the importance of various putative
mediators of inflammation in the development of the
oedema induced by OVA, in the hindpaw of sensitized
rats. The effects of anti-inflammatory, anti-histamine
and  anti-allergic  drugs  against  anaphylactic  paw
oedema were studied.
Drug administration
One hour before the intraplantar challenge, animals
were  treated  subcutaneously  (s.c.)  with  inhibitors.
The  drugs  were  diluted  in  sterile  PBS.  In  control
animals, sterile PBS replaced the antagonists. Most of
the  doses used  in  this  study  have commonly  been
shown in the literature to inhibit the corresponding
binding sites.4,11,12
Systemic depletion of mast cells
13
Animals were pretreated i.p. with compound 48/80
during 4 days (0.6mg/kg, twice a day for 3 days and
1.2mg/kg, twice on the 4th day). On the 5th day, the
intraplantar challenge was made and the oedema was
evaluated. Animals were killed by cervical dislocation
4h after the paw challenge, and the depletion of mast
cell  population  was estimated in  groups  of  treated
animals by counting the number of mast cells in the
peritoneal cavity exudate, using toluidine blue.
Histopathological study
Animals were killed by cervical dislocation 4h after
the paw challenge. The paws were excised and the
footpads  fixed  in  10%  formalin  solution.  Paraffin
blocks were prepared using conventional techniques
and the histological sections stained with haematox-
ylin and eosin for light microscopic analysis.
Drugs and reagents
The  following  drugs  and  reagents  were  used:
chicken OVA, dimethyl sulfoxide, compound 48/80,
cromolyn,  ketotifen,  cyproheptadine,  diphenydra-
mine,  pentoxyfilline,  indomethacin,  nordihydro-
guaiaretic  acid,  NDGA  (Sigma,  St  Louis,  MO,
USA),  MK-886  (L-663,536(3-[1-(4-chlorobenzyl)-
3-t-butyl-thio-5-isopropylindol-2-yl]-2,2  dimethylpro-
panoic acid) (Calbiochem, Calbiochem, La Jolla, CA,
USA), tienotriazolobenzodiazepinic compound (WEB
2086;  Institute Pasteur, Paris, France), methysergide
(maleate;  Sandoz/Novartis,  Cambridge,  MA,  USA),
meclizine (Pfizer, S˜ ao Paulo, SP, Brazil), thalidomide
(CEME,  Bras´ õ lia,  Brazil),  chlorpromazine  (Rhodia
Farma,  S Æ ao  Paulo,  SP,  Brazil),  dexamethasone
(Decadron;  Merck  Sharp  &  Dohme,  S˜ ao  Paulo,  SP,
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Statistical analysis
The results are expressed as means ± standard error of
the mean (SEM). Statistical evaluation was undertaken
by analysis of variance (ANOVA) following Student’s
paired t-test. Statistical differences were considered
significant at p < 0.05.
Results
Dose dependence and time-course of paw
oedema induced by OVA
The  intraplantar  injection  of  10mg/paw  of  OVA
induced a sustained oedema in rats immunized with
OVA at doses up to 200mg/rat (Fig. 1). At the lowest
doses (10mg/rat) of sensitization, the oedema had a
rapid onset, peaking 1h after injection. For the dose
used  in  this  study  (30mg/rat  to  sensitization  and
OVA-induced paw oedema
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FIG. 1. Dose-dependence course of sensitization of rats prior
induction of ovalbumin (ova) – paw oedema. (a) Rats were
sham-sensitized with Al(OH)3 (control) or pre-sensitized with
ova  at  the  doses  indicated  (mg/rat)  and  14–18  days  after
challenge were  intraplantar injected  (10mg/paw).  Oedema
was evaluated 1, 2, 3 and 4h after challenge. (b) The area
under the time-course curve was determined using a trape-
zoidal rule. Each point represents the mean ± SEM for the
number of animals indicated. *Significant differences com-
pared with the sham-sensitized (control) (p < 0.05; ANOVA,
Student’s t-test).
FIG. 2. Time course of sensitization of rats prior induction of
ovalbumin (ova) – paw oedema. (a) Oedema induced by ova
(10mg/paw) injected in sham-sensitized (control), non-sensi-
tized (n.sensitized) or sensitized sens rats with ova (30mg/rat)
at different days (d) after sensitization. (b) The area under the
time-course curve was determined using a trapezoidal rule.
Each point represents the mean ± SEM for the number of
animals  (n =  6).  Significant  differences  compared  with
respective  controls:  *  compared  with  the  sham-sensitized
group (control) or ** compared with the not-sensitized group
(p < 0.05; ANOVA, Student’s t-test).10mg/paw to challenge), the oedema reached a peak
at about 2h after the challenge, followed by a gradual
decrease thereafter, and at 24h post injection it was
almost absent. Furthermore, the oedema increased up
to  21  days  after  sensitization  (Fig.  2),  while  the
highest  doses  (200mg/rat)  induced  a  long-lasting
oedema, which increased up to 28 days after sensitiza-
tion  (data  not  shown).  Non-sensitized  or  control
groups sham-sensitized with Al(OH)3 were not affec-
ted by intraplantar OVA.
Response of OVA-induced oedema to standard
antagonists
Pretreatment  of  the  animals  with  dexamethasone
(0.5mg/kg)  was  effective  in  inhibiting  allergic
oedema.  Using  non-steroidal  anti-inflammatory
agents, indomethacin (2mg/kg), MK-886 (10mg/kg),
NDGA  (60mg/kg)  and  WEB  2086  (5mg/kg),  we
found  that cyclooxygenase  and lypoxygenase  prod-
ucts do not participate in the reaction. The combina-
tion  of  indomethacin  (2mg/kg)  +  MK-886  (10mg/
kg) + ketotifen (10mg/kg) also failed to reduce the
oedema induced  by  OVA  (Table  1). All  used  doses
have  previously  been  shown  to  inhibit  the  corre-
sponding pathways of  arachidonic acid  metabolism
in rats.11
The role of mast cell and endogenous amines
on OVA-induced oedema
Vasoactive  amines  appear  to  be  involved  because
anti-histamine and anti-serotonin agents reduced the
oedema.  A  significant  inhibition  of  OVA-induced
oedema  was  observed  with  methysergide  (anti-ser-
otonin), diphenydramine (anti-histamine) and cypro-
heptadine (anti-histamine and anti-serotonin) (Table
2, and Figs 3 and 4). Inhibition induced by dipheny-
dramine was dose dependent for  all doses (25, 50,
75  and 100mg/kg,s.c.). The  highest  dose (100mg/
kg) almost completely blocked oedema formation by
R. F. G. Feitosa et al.
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1 2 3 4
PBS (n = 6) 0.70 ± 0.10 0.65 ± 0.06 0.60 ± 0.04 0.53 ± 0.03
Indomethacin (n = 6) (cyclo-oxygenase
inhibitor)
2 0.73 ± 0.05 0.63 ± 0.03 0.6 ± 0.05 0.52 ± 0.05
MK-886 (n = 5) (5-lipoxygenase inhibitor) 10 0.54 ± 0.09 0.57 ± 0.10 0.48 ± 0.08 0.39 ± 0.09
NDGA (n = 5) (cyclooxygenase and
lipoxygenase inhibitor)
60 0.72 ± 0.06 0.80 ± 0.08 0.72 ± 0.07 0.60 ± 0.06
WEB 2086 (n = 6) (PAF antagonist) 5 0.58 ± 0.02 0.60 ± 0.04 0.54 ± 0.03 0.46 ± 0.03
Ketotifen (n = 6) (mast cell stabilizer) 10 0.62 ± 0.03 0.55 ± 0.02 0.56 ± 0.03 0.50 ± 0.03
Combination (n = 6)
b – 0.56 ± 0.06 0.59 ± 0.03 0.58 ± 0.02 0.52 ± 0.02
Data expressed as the mean ± SEM of the increase in paw volume (ml).
a Ovalbumin  (10mg/100ml)  was  intraplantar  injected  and  oedema  was  measured  after  1,  2,  3  and  4h.  Number  of  animals/group  in
parentheses.
b Combination = indomethacin + MK 886 + ketotifen at indicated doses.






1 2h 3h 4h
PBS (n = 6) 0.70 ± 0.10
c 0.65 ± 0.06 0.60 ± 0.04 0.53 ± 0.03
Meclizine (n = 5) (H1 anti-histamine) 30 0.64 ± 0.06 0.52 ± 0.04 0.55 ± 0.05 0.47 ± 0.07
Methysergide (n = 5) (5-HT2 blocker) 5 0.21 ± 0.04* 0.36 ± 0.06* 0.25 ± 0.06* 0.26 ± 0.07*
Ketotifen (n = 6) (mast cell stabilizer) 10 0.62 ± 0.03 0.55 ± 0.02 0.56 ± 0.03 0.50 ± 0.03
Cromolyn (n = 6) (mast cell stabilizer) 5 0.73 ± 0.06 0.87 ± 0.06* 0.72 ± 0.04 0.61 ± 0.05
Compound 48/80 (n = 6) (depletor of mast
cell)
0.85 ± 0.05 0.92 ± 0.03* 0.84 ± 0.05* 0.68 ± 0.03*
Dexamethasone (n = 5) (glucocorticoid) 0.5 0.29 ± 0.02* 0.41 ± 0.02* 0.38 ± 0.03* 0.23 ± 0.02*
Data expressed as the mean ± SEM of the increase in paw volume (ml).
a Ovalbumin  (10mg/100ml)  was  intraplantar  injected  and  oedema  was  measured  after  1,  2,  3  and  4h.  Number  of  animals/group  in
parentheses.
*p < 0.05 (ANOVA, Student’s t-test), compared with the PBS group.OVA (Fig. 3). In contrast, meclizine (classical anti-H1)
failed to inhibit immune oedema.
Effect of mast cell stabilizer agents and
compound 48/80 on oedema induced by OVA
Pretreatment  of  animals  with  cromolyn  (disodium
cromoglycate)  slightly  influenced  the  oedema
induced  by  OVA  even  at  doses  up  to  20mg/kg.
Cromolyn  induced  stimulation  at  a  lower  dose  of
5mg/kg that was only detectable at 2h (Table 2). On
the contrary, ketotifen (10mg/kg) was not effective
(Table 2). In addition, the depletion of mast cells by
systemic  treatment  with  compound  48/80  slightly,
but  significantly,  increased  the  oedematogenic
response (Table 2).
OVA-induced paw oedema
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FIG. 3. Inhibition by diphenydramine (diphen; anti-H1) of rat
paw oedema induced by intraplantar injection of ovalbumin
(ova;  10mg/paw)  in  sensitized  rats.  Fourteen  to  18  days
before, animals were sham-sensitized (control) or sensitized
with  ovalbumin  (30mg/rat,  i.p.)  and  treated  1h  before
intraplantar challenge, with PBS  or diphenydramines.c.  at
the doses indicated. (a) Oedema was measured 1, 2, 3 and
4h after the inflammatory challenge and expressed as the
increase in paw volume (ml) above its basal volume. (b) The
area under the time-course curve was determined using a
trapezoidal rule. Each point represents the mean ± SEM for
the  number  of  animals  indicated.  *  Significant  statistical
differences compared with the PBS group (p < 0.05; ANOVA,
Student’s t-test).
FIG. 4. Inhibition by cyproheptadine (cypro;  anti-H1/5-HT2)
of  rat  paw  oedema  induced  by  intraplantar  injection  of
ovalbumin (ova; 10mg/paw) in sensitized rats. Fourteen to
18  days  before,  animals  were  sensitized  with  ovalbumin
(30mg/rat, i.p.) and treated 1h before intraplantar challenge,
with PBS or cyproheptadines.c. at the doses indicated (mg/
kg).  (a)  Oedema  was  measured  1,  2,  3  and  4h  after  the
inflammatory challenge and  expressed  as  the  increase  in
paw  volume  (ml)  above  its  basal  volume.  (b)  The  area
under the time-course curve was determined using a trape-
zoidal rule. Each point represents the mean ± SEM for the
number of animals indicated. * Significant statistical differ-
ences  compared  with  the  PBS  group  (p <  0.05;  ANOVA,
Student’s t-test).Response of immune oedema to anti-tumour
necrosis factor drugs
In the present work, the effect of drugs like thalido-
mide,  inhibitors  of  tumour  necrosis  factor  (TNF)
release,14 and  pentoxyfilline,  inhibitor  of TNF  and
interleukin-1 synthesis,15,16 was investigated. Table 3
shows that thalidomide (90mg/kg) and pentoxyfilline
(90mg/kg) did not affect the oedema induced by OVA
in rats. However, a significant inhibition by chlorpro-
mazine (inhibitor of TNF synthesis) was noted for all
doses (Table 4).
Histological study of the rat paws after
antigenic challenge
An intense infiltration of neutrophils and eosinophils
was observed in the hypodermis of the paws injected
with OVA.
Discussion
Our results clearly demonstrate that immune oedema
do not appear to be dependent on arachidonic acid
metabolism,  since  the  cyclooxygenase  inhibitor
(indomethacin),  the  59-lipoxygenase  inhibitor  (MK-
886)  and  the  PAF  antagonist  (WEB  2086),  or  the
combination of indomethacin + MK-886 + ketotifen,
exerted  no  significant  inhibition  on  this  oedema,
when tested at doses that have been commonly used.
On  the  contrary,  dexamethasone  had  a  marked
inhibitory effect on the oedema.
The inhibitory effect of dexamethasone on oedema
of the rat paw induced by OVA is probably not due to
interference with eicosanoid formation, since drugs
that  block  cyclooxygenase  and  lipoxygenase  were
ineffective. Several effects of glucocorticoids may be
explained by  their capacity to block the release of
chemotactic mediators as the metabolites of arachi-
donic acid and/or cytokines with inflammatory prop-
erties.17,18The inhibitory effect of dexamethasone on
allergic oedema may result, at least in part, from the
inhibition of the release of inflammatory cytokines.
On  the  contrary,  many  studies  indicate  that  the
adhesion molecules are upregulated in allergic inflam-
mation, and play a critical role in the pathogenesis of
allergic inflammation.19 Yamaki et al.20 analyzed the
role and  mode  of  action of the mast cell  mediator
histamine in  leucocyte–endothelium interactions in
small venules in vivo. The authors suggested that the
polymorphonuclear leukocytes rolling were sensitive
to glucocorticoid treatment, possibly via the inhibi-
tion  of  the  expression  or  function  of  leukocytic
P-selectin ligant(s).
The role of vasoactive amines was also investigated
in  this  experiment.  The  effect  of  two  chemically
R. F. G. Feitosa et al.
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1 2 3 4
PBS (n = 6) 0.68 ± 0.08 0.69 ± 0.07 0.59 ± 0.04 0.52 ± 0.03
Thalidomide (n = 6)
b 90 0.65 ± 0.07 0.71 ± 0.07 0.66 ± 0.06 0.63 ± 0.06
Penthoxyfilline (n = 6) 90 0.64 ± 0.03 0.64 ± 0.04 0.50 ± 0.04 0.48 ± 0.05
Data expressed as the mean ± SEM of the increase in paw volume (ml).
a Ovalbumin  (10mg/100ml)  was  intraplantar  injected  and  oedema  was  measured  after  1,  2,  3  and  4h.  Number  of  animals/group  in
parentheses.
b Thalidomide vehicle (dimethyl sulfoxide) did not alter the oedematogenic response.





1 2 3 4
PBS (n = 15) 0.75 ± 0.05 0.73 ± 0.04 0.66 ± 0.04 0.56 ± 0.03
Chlorpromazine (n = 6) 1 0.50 ± 0.06* 0.55 ± 0.05* 0.46 ± 0.05* 0.42 ± 0.05*
Chlorpromazine (n = 6) 3 0.55 ± 0.07* 0.58 ± 0.08* 0.51 ± 0.07* 0.4 ± 0.06*
Chlorpromazine (n = 6) 9 0.26 ± 0.05* 0.29 ± 0.02* 0.28 ± 0.05* 0.23 ± 0.04*
Chlorpromazine (n = 6) 18 0.29 ± 0.04* 0.34 ± 0.4* 0.29 ± 0.04* 0.31 ± 0.03*
Data expressed as the mean ± SEM of the increase in paw volume (ml).
a Ovalbumin  (10mg/100ml)  was  intraplantar  injected  and  oedema  was  measured  after  1,  2,  3  and  4h.  Number  of  animals/group  in
parentheses.
*p < 0.05 (ANOVA, Student’s t-test), compared with the PBS group.distinct  hydrogen  antagonists,  meclizine  and
diphenydramine, was tested. It was found that only
diphenydramine  caused  reduction  in  the  immune
oedema  in  a  dose-dependent  manner.  In  addition,
methysergide  (serotonin  antagonist)  inhibited  OVA-
induced  oedema  with  optimal  effect  at  a  dose  of
5mg/kg, as  well  as  cyproheptadine (histamine  and
serotonin antagonist), suggesting the involvement of
endogenous amines, probably serotonin.
Although diphenhydramine has a well-established
H1anti-histamine action, its anti-oedematogenic effect
in the sensitized rat may not necessarily be associated
with this property, since meclizine (classical anti-H1)
failed to block the oedema. Thus, histamine seems not
to  be  involved.  Meclizine’s  lack  of  effect  is  not
surprising,  since  histamine  is  not  an  important
mediator of vascular permeability in rats.21Tromp et
al.22 investigated the role of mast cells and histamine
in  leukocyte–endothelium  interactions  in  four  rat
strains: Brown Norway, Lewis, Sprague–Dawley and
Wistar.  In  Sprague–Dawley  rats,  the  topical  admin-
istration of histamine (10–4M) resulted in a significant
increase  in  the  level  of  leukocyte  rolling  and  a
decrease in  the rolling  velocity compared with the
time control. Histamine induced leukocyte adhesion
only in the Brown Norway strain.
Additionally,  studies  have  apparently  divided  the
anti-histamine  drugs  into  two  classes:  those  com-
pounds  that  release  histamine  and  serotonin  from
isolated  rat  peritoneal  mast  cells,  and  those  that
inhibit the release of these mediators by compound
48/80.12 Possible  different  effects  of  the  anti-hista-
mine  drugs have also been investigated. Diphenhy-
dramine  appears  to  be  effective  in  inhibiting  ser-
otonin  uptake.23 Maling  et  al.12 showed  that
diphenhydramine  inhibits  oedema  induced  by  ser-
otonin in rats. Thus, we speculate a possible effect of
this drug on the depletion of serotonin.
Serotonin is a naturally occurring amine with major
effects on a variety of bodily functions.24 Important
studies  concerning  serotonin  have  focused  on  vas-
cular and inflammatory responses. Owen25 suggested
that administering serotonin to the plantar surface of
the  rat  hind  paw  caused  oedema  with  striking
extravasation of albumin. Serotonin was also reported
to induce plasma extravasation as a result of oedema
formation  in  other  models.26,27 In  addition,  cypro-
heptadine  is  a  drug  that  shows  high  affinity  for
serotonin  type  2  (5-HT2)  receptors.28 Honrubia  et
al.28 showed  that  the  activity  of  cyproheptadine
derivatives  at  5-HT2 receptors  is  related  to  these
molecular features, which make feasible a common
disposition to interact with all three 5-HT2 subtypes.
Since  methysergide,  primarily  a  serotonin  type  2
(5-HT2)  antagonist,29 and  cyproheptadine,  anti-
H1/5-HT2,28,30 are  active  inhibitors  of  oedema,  we
suggest that serotonin may be an important mediator
in  the  formation  of  oedema  induced  by  OVA  in
sensitized rats, being the binding site of the receptor
5-HT2.
On  the  contrary,  the  mast  cell  stabilizer  com-
pounds,  cromolyn  and  ketotifen,  had  a  slight  or
no  effect  in  this  oedema.  Cromolyn  (disodium
cromoglycate)  pretreatment  only  slightly  influ-
enced the  inflammatory response. Results  showed
that cromolyn at lower doses (5mg/kg) slightly and
temporarily (2h) increased the oedema, whereas at
higher  doses  (20mg/kg)  it  slightly  reduced  the
oedema  only  in  young  rats  (about  130g  body
weight)  (data not shown). The action of  cromolyn
on  inflammation  remains  uncertain.  This  drug
inhibits  mast  cell  degranulation  and  has  a  direct
effect  on  inflammatory cells.  Shida31 suggests  that
cromolyn probably, non-specifically, targets the sur-
face  of  relevant  cells  including  mast  cells  and
eosinophils. In addition, some studies suggest  that
cromolyn  diminishes  cell  activation.19,32 In  this
study,  the  stimulatory  effect  at  lower  doses  sug-
gests that the involvement of mast cells may be in
the inhibition of this oedema, while the inhibitory
effect at higher doses in young rats may be due to
a  direct  effect  on  immune-inflammatory  immature
cells,  or  due  to  another  mechanism  of  unknown
basis.
Compound 48/80 is known as a potent inducer of
degranulation  and  of  the  release,  from  connective
tissue-type mast cells, of histamine and other chem-
ical mediators, which are responsible for anaphylactic
syntoms.1 In  this  work,  OVA-induced  oedema  was
given potential by subchronic treatment by the mast
cell degranulator compound 48/80. Thus, the involve-
ment of mast cells may occur in the inhibition of this
oedema.
Histological analysis of the hind-paw 4h after the
paw  challenge  showed  an  intense  infiltration  of
neutrophils and eosinophils in the hypodermis of the
paws injected with OVA (data not shown). Consider-
ing that in the OVA-injected paw there is a migration
of  neutrophils and  eosinophils  to the  extravascular
tissues, we attributed the contribution of leukocyte
migration to the development of allergic oedema. In
addition,  TNFa induces  neutrophil  migration  in
immune  inflammation.33 Thus,  we  investigated  the
possibility  that TNFa could  be  responsible  for  the
neutrophils’  chemotactic  activity.  Anti-TNF  agents
were  ineffective  against  OVA-induced  oedema. Pen-
toxifylline  is  a  methylxanthine-derivative  drug  that
has been used for more than 20 years in the treatment
of peripheral vascular disease. Pentoxifylline is also a
potent inhibitor of TNFa secretion, both in vitro and
in  vivo,  and  has  demonstrated  its  efficacy  in  the
treatment of certain animal and human inflammatory
diseases.16 Furthermore, thalidomide exerts its inhibi-
tory action on TNFa by  enhancing mRNA degrada-
tion.14Our data suggest that the factor responsible for
inducing cell migration is different from TNFa, since
OVA-induced paw oedema
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immune oedema.
Additionally,  in  this  study  a  wide  range of  doses
were  used  for  chlorpromazine  (inhibitor  of  TNF
synthesis and implicated in several others functions),
due  to  exploreing  this  new  literature  data  in  this
specific model. A significant inhibition by this drug
was noted at all doses in this study. At higher doses
(18mg/kg),  chlorpromazine  produced  a  highly  sig-
nificant reduction in the oedematogenic effect. Chlor-
promazine, a phenothiazine derivative, possesses anti-
inflammatory  properties,  inhibiting TNFa synthesis
and bone resorption.34Also, the anti-serotonin effects
of chlorpromazine at the 5HT2 site have been well
characterized.35Trichard et al.36 suggest a high level
of 5-HT2A blockage with high doses of chlorproma-
zine. Its anti-histamine properties, however, are less
well known.
In conclusion, the present work shows that the fact
that  indomethacin,  MK-886,  NDGA  and WEB  2086
have  not  been  able  to  inhibit  allergic  oedema,
indicating that the action of  dexamethasone seems
not to be via phospholipase A2, but possibly due to
the synthesis and/or activity inhibition of pro-inflam-
matory cytokines or via the inhibition of expression
or  function  of  adhesion  molecules.  Our  results
suggest  that  anaphylactic  rat  paw  oedema  is  inde-
pendent of histamine action. The paw oedema inhibi-
tion  by  diphenhydramine,  but  not  by  meclizine
(classical anti-H1), may suggest a different mechanism,
which is independent from the anti-histamine effect.
These  data  suggest  a  role  for  serotonin  in  the  rat
oedema  induced  by  OVA,  since  methysergide  and
cyproheptadine  were  active  inhibitors  of  this
oedema. Thus, we speculate that serotonin is largely
responsible  for  immunological  oedema  in  rats,  via
5-HT2 receptors, besides  a  possible  involvement  of
other mediators, probably cytokines.
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